Clinical trials: Castrate-resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies the safety, tolerability and how well durvalumab and tremelimumab work in treating participants with castration-resistant prostate cancer who have not received chemotherapy (chemotherapy naïve) and has…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT03204812
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate safety and efficacy of Omnitarg (Pertuzumab) on cancerous lesions in men with castration-resistant (hormone-refractory) prostate cancer.
- Trial name
- NCT00058539
- Testing
- rhuMAb 2C4 (pertuzumab)
- Volunteers
- 42 people
- Sponsor
- Genentech, Inc.
Prostatic Neoplasms
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with…
- Trial name
- NCT02257736
- Testing
- Apalutamide, Abiraterone acetate, Prednisone
- Where
- 173 sites in United States, Argentina and 14 more
- Volunteers
- 982 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lymph nodes) and no longer…
- Trial name
- NCT01834651
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Edwin Posadas, MD
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This partially randomized phase I/II trial studies the side effects and how well sirolimus works when given together with docetaxel and carboplatin in treating patients with castration-resistant prostate cancer that has spread to…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7, Metastatic Malignant Neoplasm in the Bone
- Trial name
- NCT02565901
- Testing
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Prostate Cancer
Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy
The purpose of this study is to test the safety of ketoconazole and how well it works after chemotherapy has been used. Ketoconazole at lower doses has been used for fungal infections however has not yet been approved by the Food…
- Trial name
- NCT00895310
- Testing
- Ketoconazole, Hydrocortisone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Davis
Metastatic Castration-resistant Prostate Cancer
A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients
This is a randomized, multi-center, double-blind, Phase III study of radium-223 plus enzalutamide or darolutamide compared to enzalutamide or darolutamide treatment plus placebo.
- Trial name
- ESCALATE (NCT04237584)
- Testing
- Enzalutamide during Lead-in Period, Lead-in Enzalutamide followed by Radium-223/Enzalutamide, Darolutamide during Lead-in Period
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- MANA RBM
Prostate Adenocarcinoma
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Cabozantinib (XL184) is a new drug that is being developed to treat cancer. Cabozantinib works by blocking the "angiogenesis," or the growth of new blood vessels, to the tumor.
- Trial name
- NCT01347788
- Testing
- cabozantinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer.
- Trial name
- CYCLONE 2 (NCT03706365)
- Testing
- Abemaciclib, Abiraterone acetate, Prednisone
- Where
- 112 sites in United States, Australia and 9 more
- Volunteers
- 393 people
- Sponsor
- Eli Lilly and Company
Castration-Resistant Prostate Cancer
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
- Trial name
- AFFIRM (NCT00974311)
- Testing
- Enzalutamide
- Where
- 249 sites in United States, Argentina and 13 more
- Volunteers
- 1,199 people
- Sponsor
- Pfizer
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of Chinese men with metastatic castration-resistant prostate cancer (mCRPC) who have not…
- Trial name
- NCT04907227
- Testing
- Pembrolizumab, Docetaxel, Prednisone
- Where
- 20 sites in China
- Volunteers
- 81 people
- Sponsor
- Merck Sharp & Dohme LLC
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT03517969
- Testing
- Berzosertib, Carboplatin, Docetaxel
- Where
- 23 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer Metastatic
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
The purpose of this study is to look at the effects of cabozantinib on castrate-resistant prostate cancer metastatic (cancer that has spread to other parts of the body) to the bone and to learn about any side effects caused by…
- Trial name
- NCT01428219
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed…
- Trial name
- NCT01193257
- Testing
- Orteronel, Prednisone
- Where
- 78 sites in United States, Australia and 12 more
- Volunteers
- 1,099 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT03419234
- Testing
- Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel
- Where
- 672 sites in United States, Puerto Rico
- Volunteers
- 223 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Cancer, Prostatic Neoplasms
Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
This is a Phase Ib/IIa Study of Cabazitaxel plus Bavituximab in patients with castration-resistant prostate cancer (CRPC). The current study is designed to determine if the addition of bavituximab to cabazitaxel will improve…
- Trial name
- NCT01335204
- Testing
- Cabazitaxel plus bavituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Medical University of South Carolina
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CATCH-R (NCT04676334)
- Testing
- Rucaparib
- Where
- 25 sites in Canada, Israel and 4 more
- Volunteers
- 34 people
- Sponsor
- pharmaand GmbH
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
This partially randomized phase I/II trial studies cabazitaxel with or without carboplatin in treating patients with previously treated prostate cancer that has spread to other areas of the body and does not respond to treatment…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma
- Trial name
- NCT01505868
- Testing
- Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 170 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Castration-resistant Prostate Cancer
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Trial name
- NCT04556617
- Testing
- PLX2853 20 mg, Olaparib, Abiraterone acetate
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Opna Bio LLC
Prostate Cancer
Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T
This is a clinical research study of an investigational (FDA IND-BB 10091) treatment of subjects with castration-resistant prostate cancer resistant to Taxanes (docetaxel, cabazitaxel) and evidence of disease progression on…
- Trial name
- NCT01174368
- Testing
- Cancer Macrobead placement in abdominal cavity
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The Rogosin Institute